Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.## Immuneering's drug atebimetinib has shown promising results in doubling overall survival in pancreatic cancer patients after nine months. Truist analysts have deemed the results encouraging, although some unknowns remain in the data. Immuneering plans to initiate a registrational trial for atebimetinib later this year. ## In other news, Lilly has halted a mid-stage obesity study for strategic reasons, Harmony has failed a pivotal trial for fragile X syndrome, and the FDA has released guidance to streamline the development of cell and gene therapies. Overall, Immuneering's drug shows potential in improving survival rates for pancreatic cancer patients, with further trials planned for the future.

Support the show